Luteinizing hormone

Premom Easy@Home Named Top Ovulation Test Strips by The Bump

Retrieved on: 
Monday, November 20, 2023
Pregnancy, Woman, Parent, Google Play, Luteinizing hormone, App Store (iOS/iPadOS), Fertility, Temperature, Bump, Ovulation, Birth control

Burr Ridge, IL, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Premom Easy@Home ovulation test strips were named by the reputable site, The Bump, as the 2023 Best Ovulation Test Strips in the Best of The Bump Awards, an annual contest where the site rigorously tests a variety of baby and pregnancy products for new and aspiring parents1.

Key Points: 
  • Burr Ridge, IL, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Premom Easy@Home ovulation test strips were named by the reputable site, The Bump, as the 2023 Best Ovulation Test Strips in the Best of The Bump Awards, an annual contest where the site rigorously tests a variety of baby and pregnancy products for new and aspiring parents1.
  • Easy@Home’s Ovulation Test Strips are designed to assist women in identifying their most fertile days with ease and precision.
  • What sets Easy@Home apart is the integration of their ovulation test strips with the innovative Premom Ovulation Tracker app , one of the top fertility tracker apps available.
  • Premom Easy@Home ovulation & pregnancy test strips can be purchased through leading online retailers, ensuring easy accessibility for women on their fertility journey.

OOVA Launches Perimenopause Hormone Kit, First-of-its-Kind Estrogen Biomarker and App with Real-Time Data Tracking

Retrieved on: 
Wednesday, December 6, 2023
Woman, Genetics, Fertility, LH, HIPPA, Patient, Algorithm, Machine learning, Hormone replacement therapy, Ovulation, Health, Luteinizing hormone, Blood, HRT, Progesterone, Biomarker, Physician, Menopause, E3G, Birth control, Pharmaceutical industry

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Oova, Inc., the leading women's health platform revolutionizing remote hormone monitoring, announced today the launch of its at-home Perimenopause Hormone Kit. The kit is complete with urine-based, multi-hormone biomarkers including estrogen (E3G) and an app with real-time data tracking. Unlike other options on the market, which rely on blood or FSH-only urine tests that only capture a moment in time, Oova users are able to measure their actual hormone fluctuations across a 15-day period throughout a single cycle and their progress month-over-month. This gives women and their physicians insights into their perimenopause journey.

Key Points: 
  • The kit is complete with urine-based, multi-hormone biomarkers including estrogen (E3G) and an app with real-time data tracking.
  • Insights include measuring perimenopausal hormone activity, tracking unique physical symptoms, indicating fertility and confirming ovulation for those trying to conceive during perimenopause.
  • With the Perimenopause Hormone Kit, women can better understand their bodies, while tracking data that empowers them to make informed decisions with their physicians."
  • Also available is The Oova Perimenopause Membership Kit ($129.99/month) for an ongoing test strip subscription with full-circle support from Oova's hormone specialists and access to the Oova community.

Oova, Inc.'s Study Harnesses Hormone Data and Age to Precisely Determine Cycle Day within the Menstrual Cycle

Retrieved on: 
Thursday, August 3, 2023
Menstrual cycle, Pregnancy, Luteal phase, Obstetrics, Urine, Ovulation, IRMS, Follicular phase, LH, Woman, Research, Doctor of Philosophy, Luteinizing hormone, MD, Collection, PCOS, Patient, Gynaecology, Textbook, Key finding attacks, St. Barnabas' Hospital (Osaka), Massachusetts General Hospital, Female, Birth control, Medicina, MDPI

NEW YORK, Aug. 3, 2023  /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled "Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle." Conducted by esteemed scientists and co-authors, led by Dr. Amy Divaraniya, PhD founder of Oova, Inc., Dr. Mark B. Woodland, MD, Chair of Obstetrics and Gynecology at Tower Health, and Elinor Hills, content and brand lead at Oova, Inc, their discoveries bring a new understanding of the female reproductive cycle, particularly women with irregular periods, and confirms just how advanced and accurate remote hormone tracking has become.

Key Points: 
  • NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Oova, Inc. is proud to announce the publication of its latest groundbreaking study in MDPI journal, Medicina, titled " Using Hormone Data and Age to Pinpoint Cycle Day within the Menstrual Cycle ."
  • Adding to Oova's extensive collection of research and data on women's hormone levels, the study challenges the standard norms used for comparison and disproves the assumption of a 28-day reproductive cycle.
  • In this study, the Oova team evaluated hormone data from 4,123 cycles across 1,233 users, analyzing and tracking the LH and PdG via urine tests throughout menstrual cycles across different age groups.
  • Using Oova's hormone data to train their algorithm, Oova can now determine a woman's cycle day based on her age and hormone levels with 95% confidence.

Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

Retrieved on: 
Monday, July 10, 2023
Health, Consumer, Women, Research, Science, Pharmaceutical, Biotechnology, Hypersensitivity, Vaginal bleeding, News, Gonadotropin, Ganirelix, Pregnancy, Anaphylaxis, Society, Ovarian hyperstimulation syndrome, Fresenius (company), American Society for Reproductive Medicine, Parent, Ovulation, LH, Woman, ART, Infertility, Multimedia, USP, Fertilisation, Luteinizing hormone, Abdominal pain, ML, Injection site reaction, Assisted reproductive technology, LaTeX, Patient, Physician, Risk, Injection, Fertility, HCG, SART, Nausea, Gonadotropin-releasing hormone, Reproductive medicine, FDA, Headache, Syringe, Pharmaceutical industry, Birth control, Organon

Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.

Key Points: 
  • Fresenius Kabi announced today it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.
  • Ganirelix Acetate Injection is available immediately from Fresenius Kabi in 250 mcg/0.5 mL prefilled syringes.
  • View the full release here: https://www.businesswire.com/news/home/20230710582430/en/
    Now available: Fresenius Kabi Ganirelix Acetate Injection.
  • Ganirelix Acetate Injection is the third product offering in Fresenius Kabi’s Women’s Health portfolio, which includes Chorionic Gonadotropin for Injection, USP (hCG) and Progesterone Injection, USP.

Oova, Inc. and HealthKick Partner to Provide Enhanced Women's Health Benefits for Employers and Employees

Retrieved on: 
Thursday, April 27, 2023
Business development, Partnership, Smartphone, Biotechnology, Overalls, Woman, Biomarker, Privacy, Luteinizing hormone, Marketing, Machine learning, Algorithm, Fertility, Progesterone, Health, Environment, Family, Health insurance

NEW YORK, April 27, 2023 /PRNewswire-PRWeb/ -- Oova, Inc., and HealthKick announced today that the companies had entered a strategic partnership to offer Oova's fertility technology across their platform. The partnership will make Oova's at-home hormone monitoring solution available to HealthKick's employers and employees.

Key Points: 
  • The partnership will make Oova's at-home hormone monitoring solution available to HealthKick's employers and employees.
  • "Employers can no longer offer basic health benefits without including complete wellness benefits that fit each individual employee's personal goals.
  • "HealthKick truly understands that hormone health is a large part of their employees' overall health.
  • We account for 51% of the population and have different health needs," said Amy Divaraniya, Ph.D., Founder and CEO, Oova.

Antev Receives US FDA Guidance on Teverelix® Phase 3 Trial Design for Treating Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

Retrieved on: 
Wednesday, March 8, 2023
History, Mortality, Phase 3, Circulatory system, CMO, Follicle-stimulating hormone, Prostate cancer, Cardiovascular disease, Death, Standard of care, Cancer, ADT, CVD, FDA, Principal Scientific Adviser to the Government of India, Hormone, Breast, Bray, Pituitary gland, Patient, Disease, GenesisCare, Follicle, Prostate, Treatment, MACE, Personalized medicine, American Heart Association, Testosterone, Incidence, Prevalence, Androgen deprivation therapy, Luteinizing hormone, Gonadotropin-releasing hormone, US Foods, Risk, Pharmaceutical industry, Medical imaging, Birth control, Ernst Antevs

Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.

Key Points: 
  • Up to 30% of advanced prostate cancer patients on Androgen Deprivation Therapy have pre-existing Cardiovascular Disease.
  • This would be the first Phase 3 trial for a specific label to treat prostate cancer in patients with increased cardiovascular risk, addressing a significant need for prostate cancer drugs with a better cardiac toxicity profile.
  • Teverelix, a decapeptide, has the potential to be the first hormone therapy specifically approved to treat advanced prostate cancer patients with a history of cardiovascular disease.
  • “We are delighted to reach this critical milestone in Antev’s journey to secure regulatory guidance to develop Teverelix in advanced prostate cancer patients with increased cardiovascular risk,” commented Amit Kohli, Chief Executive Officer of Antev.

Proov Announces Fourth Patent to Identify Fertile Window

Retrieved on: 
Monday, January 30, 2023
Hormone, Luteinizing hormone, Ovulation, Health, Menstrual cycle, LH, Amazon, FSH, FDA, Progesterone, Patent, Urine, Fertility, Woman, Patient, Ovary, Birth control

BOULDER, Colo., Jan. 30, 2023 /PRNewswire/ -- Proov , a diagnostics company offering medical grade at-home tests and a support platform, is announcing today that it has received patent issue notification for its fourth utility patent.

Key Points: 
  • BOULDER, Colo., Jan. 30, 2023 /PRNewswire/ -- Proov , a diagnostics company offering medical grade at-home tests and a support platform, is announcing today that it has received patent issue notification for its fourth utility patent.
  • Proov's fourth patent adds to Proov's industry-leading patent portfolio, related to the testing of PdG in urine in women.
  • The new patent encompasses a system that measures follicle-stimulating hormones (FSH), estrogen, LH, and progesterone markers in urine to pinpoint the fertile window in women.
  • Proov continues to lead the development of at-home hormone testing technologies to empower women, and has many additional related technologies covered by pending patent applications.

OB-GYN Mary Jane Minkin, M.D., Shares Considerations for Women’s Health Resolutions in 2023

Retrieved on: 
Thursday, January 5, 2023
Mental Health, General Health, Family, Fitness & Nutrition, Consumer, Other Retail, Vitamins, Supplements, Supermarket, Health, Retail, Other Health, Other Consumer, Teens, Women, Children, Online Retail, Baby, Maternity, Luteinizing hormone, Gynaecology, Mental health, Ovulation, Anxiety, Menopause, Pain, Make, Vulva, Fertility, Smoking, Multivitamin, Water, Vitamin, Depression, Sleep, Woman, Vegetable, LH, Pregnancy, HCP, Yale School of Medicine, Birth, Reproductive Sciences, Moisturizer, Nutrient, Exercise, Diet, Health, PH, Reflexive pronoun, Vagina, Vaginal lubrication, Ageing, Habit, Dry, Menstrual cycle, Reproductive health, Medicine, Birth control, Obstetrics, Lactobacillus

Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.

Key Points: 
  • Top considerations for resolutions often involve improving one’s health, such as sticking to a fitness routine or committing to a proper diet.
  • "Making goals for the new year is a great way to re-evaluate one’s health routines," says Dr. Minkin.
  • “I encourage women to consider all the different changes – large or small – that they can make to improve their health and wellbeing from vaginal, sexual and reproductive health to mental health."
  • Dr. Minkin offers the following considerations for women’s health resolutions in the new year.

Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM

Retrieved on: 
Thursday, October 27, 2022
Projection, Reproductive medicine, Mannitol, Review, Merck Group, ASRM, Assisted reproductive technology, Industry, FDA, Patient, Company, Injection, Fertilisation, Nasal spray, CGT, Gonadotropin-releasing hormone, ART, Luteinizing hormone, Society, Conference, Multimedia, Akorn, Egg, Merck, Menstrual cycle, Allergy, Merck Serono, Ovulation, Pharmaceutical industry, Birth control, IQVIA, Cetrorelix

GURNEE, Ill., Oct. 27, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference (ASRM) Conference in Anaheim, California. ASRM brings together leading medical professionals to discover the latest in reproductive medicine, treatments, and patient management. Cetrorelix is the first approved, AP–rated and bioequivalent version of EMD Serono's Cetrotide®.1

Key Points: 
  • GURNEE, Ill., Oct. 27, 2022 /PRNewswire/ -- Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference (ASRM) Conference in Anaheim, California.
  • Cetrorelix is the first approved, APrated and bioequivalent version of EMD Serono's Cetrotide.1
    "We are pleased to introduce Cetrorelix to attendees at the ASRM conference," says Akorn President and CEO Douglas Boothe.
  • The FDA granted Akorn a Competitive Generic Therapy (CGT) designation for Cetrorelix, a designation intended to incentivize effective development, efficient review, and timely market entry of drugs for which there is inadequate generic competition.
  • Do not use Cetrorelix if you:
    are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to cetrorelix acetate for injection); or
    are pregnant, or think that you might be pregnant, or if you are breastfeeding.

The Worldwide Male Hypogonadism Industry is Expected to Reach $5 Billion by 2030

Retrieved on: 
Monday, October 24, 2022
Spermatozoon, Hypogonadism, FSH, Testosterone, Prevalence, Growth, Population, Diagnosis, Degenerative disease, GNRH, Klinefelter syndrome, CAGR, Bayer, Patient, Porter's five forces analysis, Man, Kallmann syndrome, Company, Obesity, Luteinizing hormone, Allergan, Awareness, Incidence, Diabetes, Ageing, Infertility, HCG, Benchmarking, Gonadotropin-releasing hormone, Pharmaceutical industry, Birth control, Retail, Male

The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.

Key Points: 
  • The global male hypogonadism market was valued $ 3,072.86 million in 2020 and expected to reach $ 5,085.03 million by 2030, with a CAGR of 5.1% from 2021 to 2030.
  • It is caused owing to the disorder related to the testes (primary hypogonadism) or the hypothalamic-pituitary axis (secondary hypogonadism).
  • The factors that drive the global male hypogonadism market are increase in cases of hypogonadism, surge in awareness of hypogonadism, and rise in number of treatment options.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities.